• Australian Council on Healthcare Standards (ACHS). ACHS clinical indicator users' manual 2008. ULTIMO NSW: Australian Council on Healthcare Standards (ACHS); 2007 Dec. 776 p.

Does not apply to this measure

This measure is used to assess the percentage of patients receiving ultra violet B (UVB) phototherapy where there is documented evidence of the explanation of phototherapy and side effects, during the 6 month time period.

Ultra violet B (UVB) treatment for psoriasis and eczema and other dermatological conditions is commonly used and effective. Safety issues include avoiding contra-indications, information to and consent from patients and the documentation of doses administered.

Ultra violet B (UVB) phototherapy; explanation of phototherapy and side effects

Total number of patients receiving ultra violet B (UVB) phototherapy, during the 6 month time period (see the related "Denominator Inclusions/Exclusions" field in the Complete Summary)

Total number of patients receiving ultra violet B (UVB) phototherapy where there is documented evidence of the explanation of phototherapy and side effects, during the 6 month time period (see the related "Numerator Inclusions/Exclusions" field in the Complete Summary)

• A formal consensus procedure involving experts in relevant clinical, methodological, and organizational sciences

Use of this measure to improve performance

• Australian Council on Healthcare Standards (ACHS). Australian clinical indicator report 1998-2006. Determining the potential to improve quality of care: 8th edition. ULTIMO NSW: Australian Council on Healthcare Standards (ACHS); 2007. 564 p.

Current routine use

Internal quality improvement

Ambulatory Care
Hospitals
Physician Group Practices/Clinics

Physicians

Group Clinical Practices

Unspecified

Either male or female

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Unspecified

Getting Better
Living with Illness

Patient-centeredness

Users of care only

Patients receiving ultra violet B (UVB) phototherapy, during the 6 month time period

Patients associated with provider

Inclusions
Total number of patients receiving ultra violet B (UVB) phototherapy*, during the 6 month time period

*UVB is electromagnetic radiation between the wavelengths of 290 and 320 nm. Light sources are fluorescent tubes of broad band or narrow band type.

Exclusions
Unspecified

All cases in the denominator are equally eligible to appear in the numerator

Encounter
Therapeutic Intervention

Time window brackets index event

Inclusions
Total number of patients receiving ultra violet B (UVB) phototherapy where there is documented evidence of the explanation of phototherapy and side effects*, during the 6 month time period

*Information should be given about the therapy and more common side effects including:

• Erythema/redness
• Skin tenderness
• Burn
• Skin dryness, skin itch
• Polymorphic light eruption
• Increase in cumulative risk for skin cancer

Exclusions
Unspecified

The measure results are somewhat or substantially under the control of the health care professionals, organizations and/or policymakers to whom the measure applies.

Episode of care

Administrative data
Medical record

Individual Case

Unspecified

Rate

Better quality is associated with a higher score

Unspecified

External comparison at a point in time
External comparison of time trends
Internal time comparison

Unspecified

Indicator area 2: phototherapy CI 2.7.

Australian Council on Healthcare Standards

Funding is direct Australian Council on Healthcare Standards (ACHS) funding sourced through our membership. ACHS does not receive external funding from the government or other sources.

Our terms of reference dictate the composition of the working parties that develop our indicators and include the following:

• Two Clinicians -- nominated by the relevant specialty college/association/society, one nominated to be the chair of the working party
• Private Hospital Representative -- nominated by the Australian Private Hospital Association
• Consumer Representative -- nominated by the Consumer Health Forum of Australia
• Coding Representative -- nominated by the National Centre for Clinical classification on Health
• Quality Health New Zealand, nominated by QHNZ (if applicable)
• Epidemiological/Clinical Research Representative, Director of Health Services Research Group, University of Newcastle
• Australian Council on Healthcare Standards (ACHS) Representatives -- Clinical Director, Coordinator, Administrative Assistant
• Other Expert Stakeholders, as required

None

Measure was not adapted from another source.

1998 Jan

2007 Dec

This is the current release of the measure.

• Australian Council on Healthcare Standards (ACHS). ACHS clinical indicator users' manual 2008. ULTIMO NSW: Australian Council on Healthcare Standards (ACHS); 2007 Dec. 776 p.

This NQMC measure was completed by ECRI Institute on September 11, 2008.

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions. This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without written permission from The Australian Council on Healthcare Standards (ACHS).